Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28526536

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2017 Jun
First author
Diéras V

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Jun;18(6):696-697. doi: 10.1016/S1470-2045(17)30303-0.
    note
    Source null
    related pmid
    28526537
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2017 Aug;18(8):e433. doi: 10.1016/S1470-2045(17)30527-2.
    note
    Source null
    related pmid
    28759383
    relationship
    Erratum in
  3. citation
    Nat Rev Clin Oncol. 2017 Nov;14(11):651-652. doi: 10.1038/nrclinonc.2017.123.
    note
    Source null
    related pmid
    28786416
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2018 Dec;19(12):e667. doi: 10.1016/S1470-2045(18)30848-9.
    note
    Source null
    related pmid
    30507428
    relationship
    Erratum in

Authors and identifiers

  1. name
    Diéras V
    type
    Author
  2. name
    Miles D
    type
    Author
  3. name
    Verma S
    type
    Author
  4. name
    Pegram M
    type
    Author
  5. name
    Welslau M
    type
    Author
  6. name
    Baselga J
    type
    Author
  7. name
    Krop IE
    type
    Author
  8. name
    Blackwell K
    type
    Author
  9. name
    Hoersch S
    type
    Author
  10. name
    Xu J
    type
    Author
  11. name
    Green M
    type
    Author
  12. name
    Gianni L
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Diéras V
    type
    Author
  2. name
    Miles D
    type
    Author
  3. name
    Verma S
    type
    Author
  4. name
    Pegram M
    type
    Author
  5. name
    Welslau M
    type
    Author
  6. name
    Baselga J
    type
    Author
  7. name
    Krop IE
    type
    Author
  8. name
    Blackwell K
    type
    Author
  9. name
    Hoersch S
    type
    Author
  10. name
    Xu J
    type
    Author
  11. name
    Green M
    type
    Author
  12. name
    Gianni L
    type
    Author
bibliography ids
  1. nci-bib-383bc39ec29db7cce2f33a43
book metadata
content sha256
55ced4931ebad22f29047dac49624029ca47115fb79c3463305095a6da209bb8
document type
citation
dois
  1. 10.1016/S1470-2045(17)30312-1
electronic publication date
display
2017 May 16
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28526536
immutable id
pubmed:28526536@55ced4931ebad22f29047dac49624029ca47115fb79c3463305095a6da209bb8
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
6
name
The Lancet. Oncology
nlm unique id
100957246
pages
732-742
volume
18
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Jun;18(6):696-697. doi: 10.1016/S1470-2045(17)30303-0.
    note
    Source null
    related pmid
    28526537
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2017 Aug;18(8):e433. doi: 10.1016/S1470-2045(17)30527-2.
    note
    Source null
    related pmid
    28759383
    relationship
    Erratum in
  3. citation
    Nat Rev Clin Oncol. 2017 Nov;14(11):651-652. doi: 10.1038/nrclinonc.2017.123.
    note
    Source null
    related pmid
    28786416
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2018 Dec;19(12):e667. doi: 10.1016/S1470-2045(18)30848-9.
    note
    Source null
    related pmid
    30507428
    relationship
    Erratum in
outcomes validated
false
pmid
28526536
provenance
batch id
1c173f0e18be0c6d461b
provider
NCBI PubMed ESummary
record sha256
f151d6995c5e42e024ae354f5f4fda520b300db6edc1f314d692a1ea36bef17a
response sha256
27a6f8bb5d49a8d376b07e1b1768913c558986bf73de92cdd65c8f05a5fa1e61
retrieved at
2026-09-09T23:47:25.975513+00:00
publication date
display
2017 Jun
precision
month
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28526536/
title
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.

Preserved source evidence · Not medical advice